We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On the back of positive phase 1 data, Valneva has started a phase 2 study on VLA15, currently the only Lyme disease vaccine candidate in active clinical development.